Treatment
Mosunetuzumab clinical trials
We’re tracking 32 recruiting studies that include Mosunetuzumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
Rochester, MinnesotaAges 18 years+ - NCT06442475RecruitingPhase 2
Low-dose mosunetuzumab for untreated indolent B-cell lymphoma
This trial tests a low dose of the drug mosunetuzumab for people with slow-growing B-cell lymphomas (follicular lymphoma or marginal zone lymphoma) who have not had any previous treatment. It aims to see if this drug can help control the disease with fewer side effects.
Seattle, WashingtonAges 18 years+ - NCT06594939RecruitingPhase 2
Combination chemo for elderly DLBCL patients
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
Milwaukee, WisconsinAges 70 years+ - NCT07598396RecruitingPhase 2
Mosunetuzumab for systemic lupus erythematosus treatment
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Salvador, Estado de BahiaAges 18 years+ - NCT06337318RecruitingPhase 3
Comparing two drugs for low-tumor burden follicular lymphoma
This trial compares a standard drug called rituximab to a newer medicine called mosunetuzumab for people with a slow-growing type of lymphoma that is not causing many symptoms. The goal is to see if mosunetuzumab works better and has fewer side effects.
Birmingham, AlabamaAges 18 years+ - NCT07191249RecruitingPhase 2
Mosunetuzumab for low-tumor-burden follicular lymphoma
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
HaifaAges 18 years+ - NCT05389293RecruitingPhase 2
Mosunetuzumab with or without zanubrutinib for follicular lymphoma
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06926205RecruitingPhase 2
CHOP chemo plus mosunetuzumab for Richter's syndrome first treatment
This trial tests a new immunotherapy drug (mosunetuzumab) combined with standard chemotherapy (CHOP) as the first treatment for Richter's syndrome, a fast-growing lymphoma that can arise from CLL. The goal is to see if this combination helps control the disease better than standard therapy.
Barcelona, BarcelonaAges 18–79 - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Duarte, CaliforniaAges 18 years+ - NCT06569680RecruitingPhase 2
Mosunetuzumab for untreated extranodal marginal zone lymphoma
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
Miami, FloridaAges 18 years+ - NCT07566364RecruitingPhase 2
Mosunetuzumab for Chronic Lymphocytic Leukemia with Minimal Residual Disease
This study tests a new antibody drug called mosunetuzumab in patients with chronic lymphocytic leukemia (CLL) who have already tried other treatments and still have detectable leukemia cells in their bone marrow. The drug is designed to work in a way that might help your immune system fight the remaining cancer cells.
Houston, TexasAges 18 years+ - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT04792502RecruitingPhase 2
Mosunetuzumab plus lenalidomide for untreated follicular or marginal lymphoma
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
New Haven, ConnecticutAges 18 years+ - NCT05260957RecruitingPhase 2
CAR-T, mosunetuzumab, and polatuzumab for hard-to-treat lymphoma
This Phase 2 trial tests a combination approach to treat certain aggressive, relapsed, or refractory non-Hodgkin lymphomas. It may help by using CAR-T cells (a patient-specific immune treatment) along with other lymphoma medicines to shrink or control the cancer.
Miami, FloridaAges 18–80 - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT05849857RecruitingPhase 2
Mosunetuzumab for follicular lymphoma that came back quickly
This Phase 2 study tests mosunetuzumab, an antibody treatment, for people with follicular lymphoma that relapsed (came back) or progressed soon after first treatment. It may help shrink the cancer again after early relapse or lack of response to standard therapy.
HelsinkiAges 18 years+ - NCT06006117RecruitingPhase 3
Testing a new drug combination for relapsed marginal zone lymphoma
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
AnderlechtAges 18 years+ - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06284122RecruitingPhase 3
New drug combo vs standard chemo for untreated follicular lymphoma
This study tests a new combination of two drugs (mosunetuzumab and lenalidomide) compared to standard chemo-immunotherapy for people with newly diagnosed follicular lymphoma that needs treatment. It aims to see if the new combination works better and has fewer side effects.
GrazAges 18 years+ - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT06453044RecruitingPhase 2
Study of two drugs for follicular lymphoma that came back
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06492837RecruitingPhase 2
Study of mosunetuzumab and zanubrutinib for relapsed follicular lymphoma
This trial tests a combination of two targeted drugs, mosunetuzumab and zanubrutinib, for people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
AdelaideAges 18 years+ - NCT06249191RecruitingPhase 1/Phase 2
Mosunetuzumab plus chemo for untreated high-grade B-cell lymphoma
This trial tests adding a drug called mosunetuzumab to standard chemotherapy for people with certain aggressive B-cell lymphomas. It aims to see if the combination works better than chemo alone.
Portland, OregonAges 18–75 - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+
What Mosunetuzumab is being studied for
Conditions with recruiting Mosunetuzumab studies.
Common questions
- Are there clinical trials studying Mosunetuzumab?
- Yes. Clin2 currently lists 32 recruiting studies that include Mosunetuzumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Mosunetuzumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Mosunetuzumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Mosunetuzumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.